TB-500 in tendon, ligament and musculoskeletal soft-tissue injury — evidence extract
No eligible study has been identified for TB-500 in tendon, ligament and musculoskeletal soft-tissue injury. The Institute records the question as not assessed and states what would change that.
§1Evidence extract: Tendon, ligament and musculoskeletal soft-tissue injury
§1.1Question and anchor outcome
- Population
- Acute or overuse injury of tendon, ligament or muscle, with healing assessed by imaging, function and return-to-activity endpoints.
- Intervention
- TB-500, subcutaneous or intramuscular in research contexts
- Comparator
- As used in each contributing trial; reported per trial rather than pooled across comparator types
- Anchor outcome
- Time to return to activity
Additional outcomes the Institute extracts for this indication: Pain on loading; Tendon thickness and structure on ultrasound; Re-injury rate.
§1.2Contributing trials
No trial has been identified for TB-500 in tendon, ligament and musculoskeletal soft-tissue injury. No certainty rating is issued where that is so, for the reason given at §1.3.
§1.3Why no certainty rating is issued
The Institute rates certainty in a body of evidence. Where no eligible study has been identified there is no such body, and the domain-by-domain assessment used elsewhere in this series is not rendered: an inconsistency judgement requires two estimates to be inconsistent with one another, and an imprecision judgement requires an interval. Neither exists here.
The outcome is therefore recorded as not assessed. It is listed in the certainty index under that heading rather than at the lowest rating, because a rating of very low certainty says that evidence was found and is weak, and that is not what has happened.
What would change this: a controlled study in the population stated at §1.1, reporting the anchor outcome, retrievable in a form the Institute can appraise. The evidence gaps recorded in the monograph at §9 state what such a study would need to measure.
§1.4What this extract does not establish
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy 2012;12(1):37–51. doi:10.1517/14712598.2012.634793 · PMID 22074294
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2014;11(6):663–673. doi:10.1586/14789450.2014.965159 · PMID 25382550
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.